INDIANAPOLIS, Sept. 16 /PRNewswire/ — Roche Diagnostics (SIX:
RO, ROG; OTCQX: RHHBY) announced today that it has introduced a
complete battery of STAT immunoassays for cardiac biomarker testing
on the cobas® 6000 analyzer series, an integrated system
designed for diagnostic labs with medium testing volumes. With a
9-minute duration, the assays are faster than any other cardiac
immunoassay tests currently available on an integrated platform and
enable labs to deliver results to doctors treating cardiac patients
in about half the time of standard Roche tests. The tests
complement a line of existing STAT cardiac assays for Roche’s
stand-alone platform, the cobas 4000 series.
“In critical care environments that require rapid
decision-making, this new line of STAT assays can help healthcare
facilities meet current cardiac care turnaround time guidelines,”
said Hans-Juergen Loyda, Ph.D., MBA, director of clinical
development and education at Roche Diagnostics Corporation. “Making
the tests available on the cobas 6000 series gives labs the
option to run Roche STAT assays on either stand-alone or integrated
platforms.”
The new 9-minute STAT immunoassay tests include troponin T,
troponin I, CK-MB, myoglobin and NT-proBNP and run on the cobas
e 601 analyzer, part of the cobas 6000 analyzer series,
an integrated platform that offers both clinical chemistry and
immunoassay testing. The STAT tests are virtually equivalent to
Roche’s 18-minute tests in performance, precision and
sensitivity.
The cardiac STAT assays can all be run with one simple blood
draw via the Roche OneTUBE solution, which consists of a single
lithium heparin tube that can be run on any of Roche’s integrated
platforms. By allowing a single technician to process a single draw
from a single point of entry instead of drawing multiple tubes for
cardiac tests on multiple analyzers, the OneTUBE solution helps to
simplify sample handling and reduce th
‘/>”/>